SEC Tracker
Get the app

Possible new RXRX shares

RXRXDilution

Last raise Oct 15, 2026, 424B5: 61.5M shares (11.5% of the 535M then) at $3.25, $200M gross

Known so far: no new shares from the prospectus covers read · shelf not limited by the baby-shelf rule · not yet read: warrants, converts, ATM.

Shelf room

  • Room today not capped by the baby-shelf rule ($2.0B float, Jun 30, 2025)
How this is worked out

Shelf room on the S-3ASR of Feb 12, 2025: not limited by the baby-shelf rule, because the $2.0B public float stated as of Jun 30, 2025 is $75M or more. Sources: S-3ASR Feb 12, 2025, effective Feb 12, 2025 · public float, as of Jun 30, 2025.

What could become new Recursion Pharmaceuticals (RXRX) shares: options and RSUs, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

RXRX dilution ladder

Every source of new shares on record, from the filings that created it.

622.8M outstanding; up to 659.7M fully diluted, +6%

  1. Outstandingas of Oct 26, 2026 (10-Q filed Nov 2) · share count on the cover page
    622.8M
  2. Options and RSUs36.9M RSUs10-Q Nov 2, 2026 · equity note
    +36.9M

Not stated in the filings we read: an ATM program, warrants, convertible notes.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Shares outstanding

623M

Dec 2024 to Oct 2026: from 397M to 623M.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.